Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials
Dementia and Neurocognitive Disorders · 2026 · 25 (2) · 130
DOI: 10.12779/dnd.2026.25.2.130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Neurocognitive Disorders, 2026. Verfasst von YongSoo Shim. Beteiligte Einrichtung: Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
ORCID-Profile: YongSoo Shim
Zitieren
APA
Shim, Y. (2026). Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. Dementia and Neurocognitive Disorders, 25(2), 130. https://doi.org/10.12779/dnd.2026.25.2.130
Vancouver
Shim Y. Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. Dementia and Neurocognitive Disorders. 2026;25(2):130. doi:10.12779/dnd.2026.25.2.130
BibTeX
@article{Shim2026,
author = {Shim, YongSoo},
title = {Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials},
journal = {Dementia and Neurocognitive Disorders},
year = {2026},
volume = {25},
number = {2},
pages = {130},
doi = {10.12779/dnd.2026.25.2.130}
}
EUVIMED